Zobrazeno 1 - 10
of 77
pro vyhledávání: '"Natalia Lapteva"'
Autor:
Spyridoula Vasileiou, LaQuisa Hill, Manik Kuvalekar, Aster G. Workineh, Ayumi Watanabe, Yovana Velazquez, Suhasini Lulla, Kimberly Mooney, Natalia Lapteva, Bambi J. Grilley, Helen E. Heslop, Cliona M. Rooney, Malcolm K. Brenner, Todd N. Eagar, George Carrum, Kevin A. Grimes, Ann M. Leen, Premal Lulla
Publikováno v:
Haematologica, Vol 108, Iss 7 (2022)
Defects in T-cell immunity to SARS-CoV-2 have been linked to an increased risk of severe COVID-19 (even after vaccination), persistent viral shedding and the emergence of more virulent viral variants. To address this T-cell deficit, we sought to prep
Externí odkaz:
https://doaj.org/article/fe01c9fbf22e4de38523e9244e616c26
Autor:
Valentina Hoyos, Spyridoula Vasileiou, Manik Kuvalekar, Ayumi Watanabe, Ifigeneia Tzannou, Yovana Velazquez, Matthew French-Kim, Wingchi Leung, Suhasini Lulla, Catherine Robertson, Claudette Foreman, Tao Wang, Shaun Bulsara, Natalia Lapteva, Bambi Grilley, Matthew Ellis, Charles Kent Osborne, Angela Coscio, Julie Nangia, Helen E. Heslop, Cliona M. Rooney, Juan F. Vera, Premal Lulla, Mothaffar Rimawi, Ann M. Leen
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Purpose: Adoptively transferred, ex vivo expanded multi-antigen-targeted T cells (multiTAA-T) represent a new, potentially effective, and nontoxic therapeutic approach for patients with breast cancer (BC). In this first-in-human trial, we investigate
Externí odkaz:
https://doaj.org/article/d2a1cea135ca47b2969fd4c6813e68ff
Autor:
Bilal Omer, Paul A. Castillo, Haruko Tashiro, Thomas Shum, Mai T. A. Huynh, Mara Cardenas, Miyuki Tanaka, Andrew Lewis, Tim Sauer, Robin Parihar, Natalia Lapteva, Michael Schmueck-Henneresse, Malini Mukherjee, Stephen Gottschalk, Cliona M. Rooney
Publikováno v:
Frontiers in Medicine, Vol 5 (2018)
The efficacy of T cells expressing chimeric antigen receptors (CARs) for solid tumors has been limited by insufficient CAR T cell expansion and persistence. The use of virus-specific T cells (VSTs) as carriers for CARs may overcome this limitation si
Externí odkaz:
https://doaj.org/article/b94065e18d6045f89d2146ca4b8029aa
Autor:
Natalia Lapteva, Juan F. Vera
Publikováno v:
Stem Cells International, Vol 2011 (2011)
Although ex vivo expanded T cells are currently widely used in pre-clinical and clinical trials, the complexity of manufacture remains a major impediment for broader application. In this review we discuss current protocols for the ex vivo expansion o
Externí odkaz:
https://doaj.org/article/21b310e1df30454789744d09920937f6
Autor:
David H. M. Steffin, Ibrahim N. Muhsen, LaQuisa C. Hill, Carlos A. Ramos, Nabil Ahmed, Meenakshi Hegde, Tao Wang, Mengfen Wu, Stephen Gottschalk, Sarah B. Whittle, Premal D. Lulla, Maksim Mamonkin, Bilal Omer, Rayne H. Rouce, Andras Heczey, Leonid S. Metelitsa, Bambi J. Grilley, Catherine Robertson, Virginia Torrano, Natalia Lapteva, Adrian P. Gee, Cliona M. Rooney, Malcolm K. Brenner, Helen E. Heslop
Publikováno v:
Blood. 140:16-24
Subsequent malignancies are well-documented complications in long-term follow-up of cancer patients. Recently, genetically modified immune effector (IE) cells have shown benefit in hematologic malignancies and are being evaluated in clinical trials f
Autor:
Cliona M. Rooney, Stephen M. Gottschalk, Leonid S. Metelitsa, Natalia Lapteva, Bilal Omer, Mai Huynh, Charlotte Rivas, Robin Parihar
Fig. S1 shows characterization of GD2-specific CAR-T cells. Fig. S2 shows characterization of human MDSCs. Fig. S3 shows characterization of TME xenograft model. Fig. S4 shows GD2.CAR-T cell homing and infiltration into MDSC-containing tumors after N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::172e235632002cb49c80bddf805cc570
https://doi.org/10.1158/2326-6066.22542165.v1
https://doi.org/10.1158/2326-6066.22542165.v1
Autor:
Cliona M. Rooney, Stephen M. Gottschalk, Leonid S. Metelitsa, Natalia Lapteva, Bilal Omer, Mai Huynh, Charlotte Rivas, Robin Parihar
Solid tumors are refractory to cellular immunotherapies in part because they contain suppressive immune effectors such as myeloid-derived suppressor cells (MDSCs) that inhibit cytotoxic lymphocytes. Strategies to reverse the suppressive tumor microen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ee879a054753ff8c7775a258778f03b
https://doi.org/10.1158/2326-6066.c.6549822.v1
https://doi.org/10.1158/2326-6066.c.6549822.v1
Autor:
David H. Quach, Carlos A. Ramos, Premal D. Lulla, Sandhya Sharma, Haran R. Ganesh, Nazila Nouraee, Yolanda D. Briones, Yezan F. Hadidi, Luis Becerra-Dominguez, Sachin G. Thakkar, Birju Mehta, Silvana Perconti, Emily M. Hsieh, Huimin Zhang, Bambi J. Grilley, Malcolm K. Brenner, Helen E. Heslop, Rayne H. Rouce, Natalia Lapteva, Cliona M. Rooney
Publikováno v:
Blood. 140:412-414
Autor:
Cliona M. Rooney, Malcolm K. Brenner, Helen E. Heslop, Carlos A. Ramos, Adrian P. Gee, Elizabeth Pacheco, April Durett, Aaron Orozco, Melissa Gates, Keli Sharpe, Conrad Russel Cruz, Gianpietro Dotti, Barbara Savoldo, Bilal Omer, Hao Liu, Rayne H. Rouce, Olga Dakhova, Darshana Raghavan, Manasa Hiregange, Tamara Tripic, Robert A. Krance, Swati Naik, Mina Al-Sabbagh, Lisa A. Rollins, Iulia Diaconu, Margaret Gilbert, Natalia Lapteva
Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e0f71fe82cdf65f01ec3b452c7b2622
https://doi.org/10.1158/1078-0432.22472346
https://doi.org/10.1158/1078-0432.22472346
Autor:
Cliona M. Rooney, Malcolm K. Brenner, Helen E. Heslop, Carlos A. Ramos, Adrian P. Gee, Elizabeth Pacheco, April Durett, Aaron Orozco, Melissa Gates, Keli Sharpe, Conrad Russel Cruz, Gianpietro Dotti, Barbara Savoldo, Bilal Omer, Hao Liu, Rayne H. Rouce, Olga Dakhova, Darshana Raghavan, Manasa Hiregange, Tamara Tripic, Robert A. Krance, Swati Naik, Mina Al-Sabbagh, Lisa A. Rollins, Iulia Diaconu, Margaret Gilbert, Natalia Lapteva
Purpose:Current protocols for CD19 chimeric antigen receptor–expressing T cells (CD19.CAR-T cells) require recipients to tolerate preinfusion cytoreductive chemotherapy, and the presence of sufficient target antigen on normal or malignant B cells.P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04e8d2194bcd7d99c6b8cfe15c50c87f
https://doi.org/10.1158/1078-0432.c.6528198
https://doi.org/10.1158/1078-0432.c.6528198